✦ LIBER ✦

Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma

✍ Scribed by Angevin, E.; Lopez-Martin, J. A.; Lin, C.-C.; Gschwend, J. E.; Harzstark, A.; Castellano, D.; Soria, J.-C.; Sen, P.; Chang, J.; Shi, M.; Kay, A.; Escudier, B.

Book ID: 118750749
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 566 KB
Volume: 19
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-12-2885

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disposition and metabolism of14C-dovitin

Disposition and metabolism of14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

✍ Anne-Charlotte Dubbelman, Alana Upthagrove… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 735 KB

Phase I–IIa study of BMS-690514, an EGFR

Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours

✍ Soria, Jean-Charles; Baselga, José; Hanna, Nasser; Laurie, Scott A.; Bahleda, Ra 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 343 KB

665 A PHASE I/II STUDY OF FORETINIB, AN

665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

✍ T. Yau; C.-J. Yen; P.-J. Chen; Y. Chau; R. Lencioni; H. Kallender; L.H. Ottesen; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB